Loading...
NPI 1235260795 · Salt Lake City, UT · Public Health or Welfare Agency
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
County Of Salt Lake is a public health or welfare agency provider located in Salt Lake City, Utah. This profile covers 10 Medicare and 71 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | County Of Salt Lake |
| Address | 2001 S State St |
| City | Salt Lake City |
| State | UT |
| ZIP | 84190 |
| Taxonomy | Public Health or Welfare Agency |
| NPI Enumerated | March 8, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $7.5M |
| Medicare | $110.5K |
COUNTY OF SALT LAKE is a Public Health or Welfare Agency NPI enumerated on 2007-03-08 (~19 years ago) with a highly Medicaid-weighted billing profile: lifetime Medicare revenue is $110.5K versus lifetime Medicaid revenue of $7.5M, indicating Medicaid dominates this provider’s payer mix in scale. The tenure and taxonomy together are consistent with a county-run public health operation rather than a fee-for-service clinical practice.
The provider’s Medicare activity is concentrated in vaccine administration: the precomputed top 3 Medicare codes account for 77.4% of Medicare revenue, driven by 91322 ($59.4K), 90662 ($17.9K) and 90677 ($8.7K). These codes and their descriptions (SARS–CoV–2, influenza, and pneumococcal vaccines) indicate Medicare billing is almost entirely immunization-focused rather than procedural or diagnostic care.
Medicaid revenue is extremely concentrated in a small set of public-health services: the precomputed top 3 Medicaid codes account for 93.3% of Medicaid revenue, with T1023 ($5.9M, 78.0%), 90471 ($1.1M, 14.4%) and T1017 ($71.1K, 0.9%) dominating the ledger. T1023’s $5.9M and 23.3K claims point to large-scale programmatic screening activities, while 90471’s 25.2K claims reinforce a mass immunization service line as the county’s core Medicaid operation.
On Medicare competitive standing, the provider appears as a high-percentile national participant for several vaccine codes: 91322 ranks #338 of 29357 providers nationally (99th percentile; typical, unremarkable volume), and 90662 ranks #1320 of 70752 providers nationally (98th percentile; typical, unremarkable volume). Despite those strong percentiles, the absolute Medicare revenue ($110.5K) is modest, so the county is a visible national participant for specific immunizations but not a large Medicare revenue generator overall.
On Medicaid competitive standing within Utah, the county is a dominant statewide player for multiple codes: T1023 ranks #1 of 15 providers in-state (100th percentile; extreme outlier, far above typical state volume for this code) and 90471 ranks #3 of 605 providers in-state (100th percentile; extreme outlier, far above typical state volume for this code). Numerous other vaccine and screening codes also appear at or near the top in-state (many labeled extreme outlier or 100th percentile), signaling market leadership in public-health screening and immunization delivery for Medicaid enrollees.
Operationally, claim counts and code mix point to mass immunization and program screening workflows rather than episodic clinical care: examples include 23.3K claims for T1023, 25.2K claims for 90471, 15.4K claims for 90472 and 4.8K claims for 90651. The presence of repeat-injection codes (90472) and large counts for pediatric and adult vaccines (90651, 90707, 90715) suggests school-based, clinic-day, or outreach vaccination programs consistent with county public-health operations.
The statistical labels provided underline where this entity is an outlier and where it is not: several Medicaid codes are flagged as extreme outlier or 100th percentile in-state (e.g., T1023, 90471, 91322), whereas Medicare vaccine codes can be high-percentile nationally but described as typical volume for those codes. This mixed signal indicates the county is a routine national participant for Medicare vaccine claims but a concentrated, above-typical provider of state Medicaid public-health services.
For payers and network analysts, the pattern suggests this entity functions as a contracted public-health provider: plan teams should treat much of the $7.5M Medicaid footprint as programmatic screening and mass immunization activity rather than traditional ambulatory care claims. Given the extreme concentration in T1023 and other in-state high-ranking codes, monitoring for proper program eligibility, encounter-level documentation, and reconciliation against local public-health contracts would be a reasonable operations priority while recognizing these patterns align with county-level public-health service delivery.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
10 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 540 | $110 | $59.4K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 290 | $60 | $17.9K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 40 | $230 | $8.7K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 580 | $20 | $8.7K |
| G0008 | Administration of influenza virus vaccine | 370 | $20 | $5.6K |
| 91304 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to prevent the patient from contracting COVID–19. The dosage is 5 mcg/0.5 mL. | 40 | $100 | $4K |
| 0124A | N/A | 190 | $20 | $2.9K |
| 0134A | N/A | 120 | $20 | $1.8K |
| 90688 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It uses split virus technology and is given as a 0.5 mL dose. | 90 | $20 | $1.5K |
| G0009 | Administration of pneumococcal vaccine | 40 | $20 | $630 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 10 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
71 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | 23,280 | $250 | $5.9M |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 25,160 | $40 | $1.1M |
| T1017 | Targeted case management, each 15 minutes | 1,150 | $60 | $71.1K |
| 90716 | The provider administers a live vaccine subcutaneously to protect against varicella infection. | 3,070 | $20 | $70.6K |
| 90739 | This code represents an adult–dosage vaccine product administered intramuscularly to protect against the liver disease hepatitis B. The product has a synthetic DNA called CpG added to improve the… | 1,590 | $40 | $68.2K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 850 | $70 | $55.3K |
| 90472 | This code represents each injection of a vaccine after the first; list this code in addition to the code for the first injection. | 15,390 | $1 | $46.2K |
| 90651 | This code represents a nonavalent human papillomavirus (HPV) vaccine product administered into the muscle to protect against HPV infection. The vaccine protects against nine HPV types (6, 11, 16, 18,… | 4,800 | $10 | $43.2K |
| 90473 | In this procedure, the provider administers a live attenuated vaccine through intranasal or oral route. | 810 | $40 | $35.6K |
| 90707 | This code represents an MMR vaccine product administered beneath the skin to protect against measles, mumps, and rubella (German measles). | 2,380 | $10 | $33.3K |
Showing 1–10 of 71
How this provider's Medicaid billing volume and revenue compare to other Utah providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Utah median
71 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| T1017 | Targeted case management, each 15 minutes | 26 | 60 | 760 | $70 | $1.1M |
| T1023 | Screening to determine the appropriateness of consideration of an individual for participation in a specified program, project or treatment protocol, per encounter | 1 | 20 | 240 | $240 | $808K |
| 91300 | N/A | 9 | 30 | 60 | $130 | $35K |
| 90739 | This code represents an adult–dosage vaccine product administered intramuscularly to protect against the liver disease hepatitis B. The product has a synthetic DNA called CpG added to improve the… | 1 | 10 | 90 | $40 | $20.1K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 3 | 610 | 140 | $10 | $13.8K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 1 | 10 | 50 | $110 | $13.2K |
| 90750 | The provider injects an adjuvanted vaccine into a muscle to protect the patient against varicella zoster infection. | 1 | 10 | 120 | $60 | $10.6K |
| 0052A | N/A | 2 | 10 | 460 | $20 | $10.3K |
| 0001A | N/A | 19 | 50 | 40 | $20 | $9K |
| 0012A | N/A | 10 | 20 | 80 | $40 | $8.4K |
Showing 1–10 of 71
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.